Valuation Gap: High Stock Price vs. Growth Targets

Motilal Oswal expects Zydus Wellness to achieve strong earnings growth, banking on scaling its RiteBite and CC segments. This forecast suggests a 37% annual growth in EBITDA from FY26 to FY28, a sharp increase compared to the company's past performance.

Valuation Gap: High Stock Price vs. Growth Targets

Motilal Oswal values Zydus Wellness at roughly 23 times its estimated FY27 earnings and 18 times FY28 earnings, setting a target price of ₹600. This suggests a valuation of 23 times EV/EBITDA and 30 times P/E by FY28. Currently, the stock trades near ₹495.65, with a P/E ratio around 77-79x and EV/EBITDA of about 49.3x. This means Zydus Wellness trades at a higher valuation than peers like Dabur India (P/E ~43-44x, EV/EBITDA ~32-36x) and Britannia Industries (P/E ~54-59x, EV/EBITDA ~36-37x). It is comparable to Nestle India (P/E ~81-83x, EV/EBITDA ~51x). This premium valuation is significant, particularly given the company's past earnings record.

Sector Trends and Past Performance Concerns

The Indian FMCG sector is seeing positive trends, with revenue growth expected at 6-8% in FY26 due to lower inflation and renewed consumer spending. Areas like healthy snacks are growing quickly. Zydus Wellness's focus on protein snacks and nutrition fits these trends. However, the company's own financial history shows slower growth. Over the last ten years, earnings grew only about 7-8% annually. This past performance makes achieving the brokerage's forecast of around 26% revenue growth and 37% EBITDA growth annually from FY26-28 a challenge. The stock has been volatile, trading between ₹358.54 and ₹552.40 in the past year, with modest year-to-date growth of 6.14%.

Risks and Analyst Concerns

Zydus Wellness faces significant challenges in its projected turnaround. While earnings grew around 7-8% annually over the past decade, analysts now expect EBITDA growth to accelerate rapidly, to over 20% domestically and nearly 37% overall. This ambitious target is complicated by recent financial results. Zydus Wellness reported a net loss of ₹395 million in the third quarter of FY26, mainly due to higher borrowing costs and special acquisition expenses. Integrating acquisitions like Comfort Click and Naturell is ongoing, which could lead to more costs or delayed benefits. The company has a large market value of about ₹15,770 crore, but its valuation multiples (P/E ~77-79x) seem high compared to more stable performers like Dabur India and Britannia Industries. While most analysts rate the stock a 'Buy', the average target price of around ₹512.86 indicates limited short-term upside. Some analysts have also recently kept or lowered their price targets. The company has also faced questions about unusual trading volumes, requiring explanations to the stock exchange.

Analyst Sentiment and Next Steps

Despite these risks, most analysts still recommend a 'Strong Buy' for Zydus Wellness, with average price targets suggesting potential gains. Analysts are revising their price targets based on new assumptions, with recent changes pointing to a stable or slightly more positive outlook. The company's board will meet on May 18, 2026, to review the audited financial results for the year ending March 31, 2026, which will offer more insight into its financial path.